Spots Global Cancer Trial Database for gastric
Every month we try and update this database with for gastric cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Minimally Invasive Surgery (MIS) Database for the Purpose of Research | NCT00535990 | Morbid Obesity Hernia Colorectal Canc... Laparoscopy | 18 Years - | University of California, San Diego | ||
| Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations | NCT06118658 | Gastric Colorectal Aden... | tislelizumab | 18 Years - 75 Years | China Medical University, China | |
| Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy | NCT00849979 | Gastrointestina... | Questionnaire Interview | 18 Years - | M.D. Anderson Cancer Center | |
| Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | NCT00215644 | Esophageal Canc... Gastric Cancer | Matuzumab Epirubicin Cisplatin Capecitabine | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Patient Factors Impacting Adherence to Oral Chemotherapy | NCT01487343 | Breast Cancer Gastrointestina... | questionnaire a... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma | NCT00667420 | Esophageal Aden... Gastric Adenoca... | panitumumab, ep... | 18 Years - | Massachusetts General Hospital | |
| Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | NCT00525785 | Stomach Cancer Gastric Cancer | 5-Fluorouracil Folinic Acid Oxaliplatin Radiotherapy Surgery | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Phase I Trial of Combination of FOLFIRI and SOM 230 | NCT01434069 | Gastrointestina... | SOM230C LAR FOLFIRI Infusio... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Quality of Life Among Long-Term Survivors of Resected Gastric Cancer | NCT00598546 | Gastric Cancer | EORTC QLQ-C30, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Clinical Trial at Neoadjuvant Peritoneal and Systemic Chemotherapy Plus HIPEC in Gastric Carcinomatosis | NCT01342653 | Peritoneal Carc... Gastric Cancer | Intraperitoneal... | 18 Years - 64 Years | Hospital General Universitario Gregorio Marañon | |
| Wet Heparinized Suction for Abdominal Cancer | NCT05041335 | Cancer of Pancr... Cancer of Stoma... Cancer of Esoph... Cancer of Liver Cancer | wet heparinzed ... Microsieve No heparin flus... No microsieve | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | NCT02205463 | Esophageal Canc... Stomach Cancer | KD019 | 18 Years - | NYU Langone Health | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment | NCT01262482 | Advanced or Met... | Oxaliplatin Sorafenib | 18 Years - | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | NCT01932580 | Gastric Adenoca... Esophageal Aden... | FLOT (5-fluorou... | 18 Years - | McGill University | |
| Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | NCT01932580 | Gastric Adenoca... Esophageal Aden... | FLOT (5-fluorou... | 18 Years - | McGill University | |
| Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | NCT01401907 | Non-small Cell ... Small Cell Lung... Mesothelioma Esophageal Canc... Gastric Cancer Liver Cancer Pancreatic Canc... | early palliativ... | 18 Years - | Massachusetts General Hospital | |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | NCT02213289 | Adenocarcinoma | Trastuzumab ABT-806 Bemarituzumab Ramucirumab Nivolumab Standard cytoth... | 18 Years - | University of Chicago | |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | NCT02205463 | Esophageal Canc... Stomach Cancer | KD019 | 18 Years - | NYU Langone Health | |
| Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy | NCT00849979 | Gastrointestina... | Questionnaire Interview | 18 Years - | M.D. Anderson Cancer Center | |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | NCT02213289 | Adenocarcinoma | Trastuzumab ABT-806 Bemarituzumab Ramucirumab Nivolumab Standard cytoth... | 18 Years - | University of Chicago | |
| Minimally Invasive Surgery (MIS) Database for the Purpose of Research | NCT00535990 | Morbid Obesity Hernia Colorectal Canc... Laparoscopy | 18 Years - | University of California, San Diego | ||
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | NCT05002127 | Gastric Cancer Gastroesophagea... Gastric Adenoca... | Evorpacept (ALX... Trastuzumab Ramucirumab Paclitaxel | 18 Years - | ALX Oncology Inc. | |
| Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | NCT00525785 | Stomach Cancer Gastric Cancer | 5-Fluorouracil Folinic Acid Oxaliplatin Radiotherapy Surgery | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas | NCT00620607 | Stomach Neoplas... Metastatic or L... Metastatic or L... | huC242-DM4 | 18 Years - | ImmunoGen, Inc. | |
| A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | NCT01588678 | Advanced Solid ... Lymphoma | DS-3078a | 18 Years - | Daiichi Sankyo | |
| A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | NCT02908451 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Biliary Cancer | AbGn-107 | 18 Years - | AbGenomics B.V Taiwan Branch | |
| Docetaxel and Irinotecan in Gastric Cancer | NCT04770623 | Stomach Cancer Gastric Cancer Chemotherapy Ef... | Docetaxel Irinotecan | 18 Years - 70 Years | Menoufia University | |
| Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction | NCT00080002 | Cancer of Stoma... Gastroesophagea... | Pegamotecan | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | NCT03861793 | Advanced Solid ... | ALKS 4230 Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | NCT02274012 | HER-2 Positive ... Gastrooesophage... Esophageal Canc... | Afatinib Paclitaxel | 18 Years - | Columbia University | |
| Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations | NCT06118658 | Gastric Colorectal Aden... | tislelizumab | 18 Years - 75 Years | China Medical University, China | |
| NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma | NCT01565109 | Gastric Adenoca... | Docetaxel - Cis... Radiation of 45... | 18 Years - 65 Years | Institut Sainte Catherine | |
| Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | NCT01041235 | Solid Tumor Breast Cancer Ovarian Cancer Pancreatic Canc... Non-Small Cell ... | ATI-1123 (activ... | 18 Years - | Azaya Therapeutics, Inc. | |
| Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction | NCT00374985 | Esophageal Neop... Stomach Neoplas... | Docetaxel, Oxal... Radiotherapy | 18 Years - 75 Years | Johannes Gutenberg University Mainz | |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | NCT03740256 | Bladder Cancer Head and Neck S... Cancer of the S... Lung Cancer Breast Cancer Gastric Cancer Esophageal Canc... Colorectal Canc... Pancreatic Aden... Solid Tumor | CAdVEC | 18 Years - | Baylor College of Medicine | |
| Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer | NCT01116791 | Peritoneal Carc... Gastrointestina... | Cytoreductive S... | 18 Years - 75 Years | University Hospital, Gasthuisberg | |
| Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer | NCT00675194 | Gastric Cancer | Cisplatin, Irin... | 18 Years - 75 Years | Johannes Gutenberg University Mainz | |
| Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer | NCT00675194 | Gastric Cancer | Cisplatin, Irin... | 18 Years - 75 Years | Johannes Gutenberg University Mainz | |
| Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | NCT00215644 | Esophageal Canc... Gastric Cancer | Matuzumab Epirubicin Cisplatin Capecitabine | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | NCT02283359 | Esophageal Canc... Gastric Cancer | Selinexor Irinotecan | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
